Guggenheim analyst Yatin Suneja maintains Avalo Therapeutics (NASDAQ:AVTX) with a Buy and lowers

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Avalo Therapeutics (NASDAQ:AVTX) wit

Avalo Therapeutics (NASDAQ:AVTX) reported quarterly losses of $(0.83) per share which missed the ana

WAYNE, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical st

Leerink Partners analyst Thomas Smith initiates coverage on Avalo Therapeutics (NASDAQ:AVTX) with

Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to de

Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to de

Top Wall Street analysts changed outlook on top names. Find all rating changes on Benzinga's ana

Wall Street analysts upgraded EDU, MKTX, and FORM stocks. Check out their ratings on Benzinga's

Wall Street analysts downgrade ADBE and SAIL, cutting price targets. Check other analysts' views

Top Wall Street analysts changed their outlook on top names. See analyst rating changes for PepsiCo,

B of A Securities analyst Alec Stranahan initiates coverage on Avalo Therapeutics (NASDAQ:AVTX) w

Citizens analyst Jason N. Butler maintains Avalo Therapeutics (NASDAQ:AVTX) with a Market Outperf

Avalo Therapeutics reported better-than-expected Q1 loss due to positive trial results. Analysts mai

Wedbush analyst Robert Driscoll maintains Avalo Therapeutics (NASDAQ:AVTX) with a Outperform and

Analyst ratings for top names changed: Doximity cut to neutral, National Vision lowered price target

Mizuho analyst Joseph Catanzaro maintains Avalo Therapeutics (NASDAQ:AVTX) with a Outperform and

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Avalo Therapeutics (NASDAQ:AVTX) wit

Avalo Therapeutics (NASDAQ:AVTX) reported quarterly losses of $(0.98) per share which beat the analy

Piper Sandler analyst Yasmeen Rahimi maintains Avalo Therapeutics (NASDAQ:AVTX) with a Overweight

Avalo Therapeutics Inc (NASDAQ:AVTX) shares are surging after the company delivered a major clinical

Dow Jones up 500 points, DaVita Inc (DVA) shares rise after better-than-expected earnings and raised

Citizens analyst Jason N. Butler maintains Avalo Therapeutics (NASDAQ:AVTX) with a Market Outperf

Wedbush analyst Robert Driscoll maintains Avalo Therapeutics (NASDAQ:AVTX) with a Outperform and

AMD: 21% | Advanced Micro Devices shares are trading higher after the company reported better-than-e

BTIG analyst Julian Harrison maintains Avalo Therapeutics (NASDAQ:AVTX) with a Buy and raises the

Veeco Instruments Inc (NASDAQ: VECO) rose in pre-market trading after reporting Q1 results and affir

Avalo Therapeutics Inc. rises sharply in pre-market trading following a Phase 2 trial win and a $375

Avalo Therapeutics, Inc. (NASDAQ: AVTX) ("Avalo"), a clinical-stage biotechnology company fu

Successfully met primary endpoint of HiSCR75 for both doses studied, demonstrating response rates of

BTIG analyst Julian Harrison reiterates Avalo Therapeutics (NASDAQ:AVTX) with a Buy and maintains

Wolfe Research analyst Andy Chen initiates coverage on Avalo Therapeutics (NASDAQ:AVTX) with a Ou

Wall Street analysts have changed outlooks on top stocks. For details on changes, check out analyst

Citizens analyst Jason Butler initiates coverage on Avalo Therapeutics (NASDAQ:AVTX) with a Marke

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Avalo Therapeutics (NASDAQ:AVTX) wit

BTIG analyst Julian Harrison reiterates Avalo Therapeutics (NASDAQ:AVTX) with a Buy and maintains

Avalo Therapeutics (NASDAQ:AVTX) reported quarterly losses of $(0.48) per share which beat the analy

Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading. Genmab announce

  Wednesday saw 59 companies set new 52-week lows.

  On Monday, 89 stocks made new 52-week lows.

Gainers Blue Water Vaccines, Inc. (NASDAQ: BWV) shares climbed 53.2% to close at $3.14 on Wednes

  On Friday, 1043 companies hit new 52-week lows.